Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient.
During immunosuppression with cyclosporine, gingival overgrowth, a minor secondary effect, may appear in the first weeks of treatment. In certain cases it may affect the function and/or esthetic appearance in a manner intolerable to the patient. A new immunnosuppressive molecule, tacrolimus, presently used as a treatment of second choice to control acute corticoresistant rejection, may bring oral comfort to these patients, since it reduces gingival overgrowth to negligible levels.
Bader
G
G
Service de Pathologie et Chirurgie Buccale, UFR Odontologie, CHRU Rennes, France.
Lejeune
S
S
Messner
M
M
D016572:Cyclosporine / Q000009:adverse effects*; D005885:Gingival Hyperplasia / Q000139:chemically induced / Q000517:prevention & control; D019214:Gingival Overgrowth / Q000139:chemically induced / Q000517:prevention & control*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus